Rafferty Asset Management, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 158 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is 1.46 and the average weighting 0.0%.

Quarter-by-quarter ownership
Rafferty Asset Management, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$5,677,560
+24.5%
306,233
-25.7%
0.03%
+26.9%
Q2 2023$4,559,750
+30.4%
412,274
+58.3%
0.03%
+8.3%
Q1 2023$3,497,508
+6.3%
260,425
-2.1%
0.02%
-14.3%
Q4 2022$3,289,393
+4.5%
265,917
+17.9%
0.03%
-15.2%
Q3 2022$3,147,000
+48.7%
225,604
+47.3%
0.03%
+73.7%
Q2 2022$2,116,000
-42.9%
153,193
-32.8%
0.02%
-13.6%
Q1 2022$3,707,000
-12.4%
227,843
-12.3%
0.02%0.0%
Q4 2021$4,233,000
+93.1%
259,839
+76.0%
0.02%
+46.7%
Q3 2021$2,192,000
-9.3%
147,600
+22.0%
0.02%0.0%
Q2 2021$2,416,000
-34.0%
120,991
-23.7%
0.02%
-40.0%
Q1 2021$3,660,000
+388.0%
158,592
+422.5%
0.02%
+257.1%
Q4 2020$750,000
-62.0%
30,355
-36.2%
0.01%
-70.8%
Q3 2020$1,973,000
+224.0%
47,581
+274.5%
0.02%
+166.7%
Q2 2020$609,000
+150.6%
12,704
+229.3%
0.01%
-10.0%
Q1 2020$243,000
-94.0%
3,858
-88.3%
0.01%
-84.1%
Q4 2019$4,073,000
-34.8%
32,865
-65.1%
0.06%
-35.7%
Q3 2019$6,244,000
+26.2%
94,097
+51.3%
0.10%
+12.6%
Q2 2019$4,947,000
-10.0%
62,176
+26.5%
0.09%
-1.1%
Q1 2019$5,496,00049,1350.09%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2021
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders